We are pleased to present below all posts archived in 'September, 2016'. If you still can't find what you are looking for, try using the search box.
BBI Solutions (BBI) has announced the launch of a range of antibodies for the biomarker Galectin-3. The antibodies complement BBI’s Galectin-3 antigen, which was also launched earlier this year. Available to sample now, these antibodies are highly sensitive with low cross-reactivity.
Read the rest of entry »
With NICE now focussing on the more sensitive and specific Faecal Immunochemical Tests (FIT) for triaging patients with lower gastrointestinal symptoms, it is important to protect haemoglobin in faecal samples (f-Hb) from degradation. With any method, sample integrity is key to the quality of results, so quantitative FIT systems that use a direct sampling method can help improve this.
AgPlus Diagnostics Ltd today announced that they have signed a contract with AstraZeneca to develop a prototype diagnostic. The agreement will cover AgPlus Diagnostics developing a diagnostic assay for potential use as part of a personalised approach to treating respiratory disease.
For immediate release: 22nd September 2016, Cobham, UK: A peer reviewed study led by Proteome Sciences plc (“Proteome Sciences”), in conjunction with a group of highly respected universities and hospitals, demonstrates the ability of an innovative mass spectrometry (MS) workflow to dramatically improve the ability to detect tau-derived peptides that are directly related to human Alzheimer’s pathology as early stage biomarkers of the disease.
Specialist intellectual property firm, RGC Jenkins & Co has announced this week that it is merging with Freiburg firm, Maucher Börjes Jenkins to become Maucher Jenkins.
New simple-to-use 5-part diff DxH 500 ideal for wide-ranging applications
Proteome Sciences today releases its unaudited interim results for the six months ended 30th June 2016.
Oxford, UK – 13 September 2016. Oxford Gene Technology (OGT), The Molecular Genetics Company, has launched two new CE-IVD labelled fluorescence in situhybridisation (FISH) probes, further expanding its extensive lung cancer portfolio. The Cytocell Aquarius® ROS1 Plus Breakapart and RET Breakapart probes* specifically and accurately detect rearrangements in the genome associated with the most common form of lung cancer — non-small cell lung cancer (NSCLC). The new additions complement OGT’s existing NSCLC probe range (including ALK Breakapart, EGFR Amplification and EML Breakapart), providing a comprehensive solution for diagnosis and patient stratification.
illumigene® Malaria Receives 1 st Place Award at the Journées Internationales de Biologie /Association des Colloques Nationaux des Biologistes Conference in Paris
Meridian Bioscience, Inc. (NASDAQ: VIVO) was awarded 1st place for innovation in emergency treatment and point-of-care testing for its illumigene® Malaria test at the 2016 JIB/ACNBH Conference. Innovations from worldwide companies contributing to the development of the Medical Biology industry were put under the spotlight at this year’s conference held in Paris, France, and were reviewed by worldwide expert members in the medical biology field.
Who are the BIVDA Members
Member Press Releases
Point of Care Directory
News, Policy and Media
BIVDA Press Releases